Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease


Program Dates: November 16th, 2020 - November 15th, 2021
Credits: 1.0 AMA PRA Category 1 Credit™


Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Program Overview

This CME activity will highlight advances in sphinogosine-1-phosphate (S1P) therapeutics to improve outcomes in patients with inflammatory bowel disease. The expert faculty, led by Dr. William Sandborn, will discuss how sphingosine-1-phosphate (S1P) receptor modulators are utilized as a therapeutic target to reduce inflammation in patients with inflammatory bowel disease (IBD). Recent and emerging clinical trial data on the safety and efficacy of novel S1P therapeutics to treat patients with IBD will be reviewed and analyzed. The faculty will also delve into treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes. Upon completion of this educational program, clinicians will gain better insight into how to better manage their patients with inflammatory bowel disease by utilizing S1P therapeutics.

Target Audience

Gastroenterologists, physician assistants and other healthcare providers who care for patients with IBD

Agenda

  1. Scientific Update for Sphingosine-1-Phosphate (S1P) Receptor Modulators as a Therapeutic Target for IBD
  2. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel S1P Therapeutics for the Management of Crohn’s Disease and Ulcerative Colitis Disease
  3. Treatment Strategies for the Application of S1P Therapeutics to Optimize IBD Patient Outcomes

Learning Objectives

  1. Understand the sphingosine-1-phosphate (S1P) receptor modulator as a therapeutic target to reduce inflammation in patients with IBD
  2. Analyze ongoing clinical trials for the efficacy and safety of novel S1P therapeutics to treat patients with IBD
  3. Develop treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes

Faculty

William J. Sandborn, MD
Professor and Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego
San Diego, CA

 

Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

 

David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
William J. Sandborn, MD

 

 Consultant/Advisor: AbbVie Inc.; ABIVAX; Admirx; Alfasigma USA, Inc.; Alimentiv; Alivio Therapeutics; Allakos Inc.; Amgen Inc.; Applied Molecular Transpor Inc.; Arena Pharmaceuticals, Inc.; Bausch Health Companies Inc.; BeiGene; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol Meyers Squibb Company; Celgene; Celltrion Healthcare Co.,Ltd.; Celularity Inc.; Cosmo Pharmaceuticals; Eli Lilly and Company; Escalier Biosciences; Equillium, Inc.; Forbion Capital Partners; Genentech USA, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals, Inc.; Gossamer Bio; Immunic Therapeutics; InDex Pharmaceuticals; Intact Therapeutics, Inc; Janssen Pharmaceuticals, Inc.;  Kyverna Therapeutics, Inc.; Landos Biopharma, Inc.; Oppilan Pharma Ltd.; Otsuka America Pharmaceutical, Inc.; Pandion Therapeutics; Pfizer Inc.; Progenity, Inc; Prometheus Biosciences; Protagonist Therapeutics; ProventionBio; Reistone Biopharma; Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis Pharmaceuticals LLC; Tillotts Pharma AG; UCB; Vedanta Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.; Vivelix Pharmaceuticals; Vivreon Biosciences; Zealand Pharma

Grant/Research Support: AbbVie Inc.; ABIVAX; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Celgene; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Seres Therapeutics; Shire LLC; Takeda Pharmaceutical Company; Theravance Biopharma, Inc.

Stocks: Allakos Inc.; BeiGene, Gossamer Bio; Oppilan Pharma Ltd; Prometheus Biosciences; Progenity; Shoreline Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.

Miguel Regueiro, MD  Consultant/Advisor: AbbVie Inc.; Allergan; Amgen Inc.; Arena Pharmaceuticals, Inc.; Bristol Meyers Squibb Company; Eli Lilly and Company; Genentech USA, Inc; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceutical Company; UCB

Grant/Research Support: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company

David T. Rubin, MD  Consultant/Advisor: AbbVie Inc.; AbGenomics International, Inc.; Allergan; Biomica; Boehringer Ingelheim; Bristol Meyers Squibb Company; CDx Diagnostics; Check-Cap; Dizal Pharma; Eli Lilly and Company; Galen Limited; Genentech USA, Inc.; Gilead Sciences, Inc.; Ichnos Sciences S.A.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; Takeda Pharmaceutical Company; Techlab, Inc.

Co-Founder: Cornerstone Health, Inc.; GoDuRn, LLC

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

 

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM

Financial Support

This activity has been supported by an independent educational grant from Bristol Myers Squibb Company

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

 

Provided by: AcademicCME-web